NCT04231084

Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide

Acute Hemodynamic Comparison of Inhaled Nitric Oxide and Inhaled Epoprostenol in Pulmonary Hypertension

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 115 (actual)
• Sponsor: Brigham and Women's Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The overarching goal of this study is to examine the acute vasoreactive response to both inhaled nitric oxide and inhaled epoprostenol across both traditionally and non-traditionally interrogated phenotypes in PH, and to further characterize the relationship of vasoreactivity to disease severity and PH phenotype.

Conditions

• Pulmonary Hypertension

Interventions

Type	Name	Description
DRUG	Vasodilator testing (Inhaled Nitric Oxide)	Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
DRUG	Vasodilator testing (Inhaled Epoprostenol)	Right heart catheterization with vasodilator testing with each arms' associated agent will be performed

Timeline

• Start date: 2021-01-15
• Primary completion: 2024-08-01
• Completion: 2024-08-01
• First posted: 2020-01-18
• Last updated: 2024-08-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study